Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus FLOT as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200066893Phase 2Completed
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Second Hospital of Lanzhou University. Primary endpoints: Complete response rate and Major response rate. Started Dec 2022; status: completed.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200066893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066893.